tiprankstipranks
Trending News
More News >

Arecor Therapeutics Advances with Promising Trials and Fundraise

Arecor Therapeutics Advances with Promising Trials and Fundraise

Arecor Therapeutics PLC (GB:AREC) has released an update.

Don’t Miss TipRanks’ Half-Year Sale

Arecor Therapeutics PLC reports positive interim results, including a successful Phase I trial for its insulin candidate AT278 and the expansion of its diabetes and obesity pipeline. The company’s financial position is strengthened by a £6.4 million fundraise, which will support further R&D and sales of Ogluo®, their specialty diabetes product. Arecor’s growing technology partnerships and licensing agreements signal potential future revenue growth.

For further insights into GB:AREC stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1